Is Anamorelin a hormonal drug?

Anamorelin (Anamorelin) is not a hormonal drug. It is a new type of cancer cachexia treatment drug that is widely used to treat cancer cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, colorectal cancer and other malignant tumors.

Anamulin stimulates appetite and promotes food intake by binding to the receptor of the appetite-regulating hormone ghrelin (growth hormone-releasing peptide). Specifically, it is a selective peptide receptor agonist (SPRA) that regulates appetite and weight by simulating the effect of ghrelin on its receptors. Compared with traditional hormonal drugs, anamorelin is structurally and functionally different from ordinary hormone molecules and therefore cannot be classified as a hormonal drug.

Anamorelin is mainly used in clinical applications to treat cancer cachexia, a common cancer-related complication manifested by symptoms such as significant weight loss, muscle wasting, and loss of appetite. Anamorelin helps improve patients' nutritional status and quality of life by increasing their appetite and weight. Multiple randomized controlled clinical trials have demonstrated the positive effects of anamorelin in improving patients' total body weight, lean body mass, and quality of life.

The safety profile of anamorelin is generally acceptable. It showed no significant differences compared with placebo for all adverse events, serious adverse events, overall survival and appetite. However, patients still need to consult their doctor carefully before using anamorelin and use it in accordance with the doctor's instructions to ensure safe and effective treatment.